The United Kingdom and the United States have agreed to a key commercial pact that will ensure zero tariffs on British drug shipments going into the US market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has pledged to raise expenditure on medicines through the NHS. This move secures that import taxes on these vital exports will stay at zero for a timeframe of the next three years.
This agreement comes after previous threats to significantly raise import taxes on branded pharmaceutical products, with potential rates floated reaching 100%.
"This agreement between the UK bolsters the worldwide climate for new treatments and brings much-needed balance to transatlantic pharmaceutical trade," a release noted.
Economic Impact
Pharmaceuticals constitute one of the Britain's largest export categories to the America, which is clearly the largest destination for major companies like GSK and AstraZeneca.
Trade data reveal that in the year to the end of last September, the UK sold pharmaceutical products worth £11.1bn to the US. This figure represented a significant portion of British export trade in that timeframe.
"This guarantee secures employment, boosts funding and facilitates the UK to establish itself as a global hub for biotech and pharma," a government official stated.
Key NHS Changes
The agreement entails several notable commitments from the UK:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it judges new therapies to be unaffordable by 25%.
- Boosted Medicine Funding: There is a target to increase overall public funding on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Rebate Cap: The amount manufacturers must refund to the NHS to prevent overspending will be limited at fifteen percent. Last year, refunds exceeded 20%.
Recent Tensions
This agreement comes amid a protracted dispute between the drug companies and the UK government over drug pricing and regulatory access.
The disagreement were exacerbated by arguments that US customers were paying several times more for the same drugs than patients in the UK and Europe.
Recently, several major drug company projects in the UK have been delayed or cancelled, while substantial funding commitments have been pledged toward American operations.
A senior figure acknowledged that the NHS had to invest a greater share on medicines, noting that its spending on drugs had declined as a share of its overall budget over the last ten years.
